Mark Wildgust (he/him)
@MAWildgust
Followers
1K
Following
2K
Statuses
1K
VP of Oncology Global Medical Affairs at Johnson & Johnson, focused on bringing new treatment options for pts with cancer. Tweets/views shared are my own
Raritan, NJ
Joined February 2018
Excited to see the EU CHMP approval for our @JNJInnovMed SubQ version of our #amivantamab. #MyCompany
1
1
6
Excited to share the SKIPPirr study is now published, using dexamethasone to prevent and reduce Infusion-Related Reactions (IRRs). #EGFR #NSCLC #MyCompany
1
1
9
@UrologyTimes article on our @JNJInnovMed New Drug Application that we have initiated with FDA for TAR-200. #MyCompany via @@urologytimes
0
0
0
Enjoyed talking to @biospace about the advanced we have made collectively in helping patients with #Myeloma. I am humbled to have been part of this effort! @JNJInnovMed we are working hard to redefine outcomes for patients. #MyCompany
0
1
7
So excited to share the #COCOON study met its primary endpoint. Thank you @jillfeldman4 & thank you to all the investigators and most importantly the patients who made this study possible. To my @JNJInnovMed team, you were amazing! #My Company
1
2
11
For pts with non-muscle invasive bladder cancer #NMIBC who no longer respond to BCG & with high risk features, outcomes are poor. To have a new treatment for these pts would be amazing. I am celebrating today with news @JNJInnovMed. #MyCompany
0
2
4
@jillfeldman4 Thank you Jill. Your input, your guidance, your voice and your leadership has been so important for COCOON. #MyCompany
0
1
6
RT @APassaroMD: COCOON study meets primary endpoint demonstrating statistically significant and clinically meaningful reduction in dermatol…
0
20
0
@Exon20Group Thank you @Exon20Group. We are excited to share the reaching of the OS milestone. We are thankful to share the press release and excited to share the results shortly at an upcoming medical meeting.
0
0
0
RT @JNJInnovMed: #BREAKING: Topline results for the key secondary endpoint of overall survival from the Phase 3 MARIPOSA study highlight tr…
0
10
0
RT @APassaroMD: 🚨Major breakthrough from #PressRelease The MARIPOSA study reports a statistically significant and clinically meaningful im…
0
24
0
Update on #Mariposa study for #EGFR #NSCLC from @JNJInnovation. Providing more hope for patients. #MyCompany
0
1
11
RT @StephenVLiu: Press release: MARIPOSA regimen of first-line amivantamab plus lazertinib shows a significant improvement in overall survi…
0
42
0
RT @JoshuaRichterMD: Newly updated NCCN guidelines. Now allows for prophylactic toci with Teclistamab . Are you changing practice ? #m…
0
17
0
Great to see my colleague Deeksha Vishwamitra presenting on PD dynamics with Talquetamab or Teclistamab with daratumumab and pomalidomide. #MyCompany #ASH24
1
0
6